江苏荃信生物医药有限公司

Qyuns Therapeutics Co., Ltd., established in 2015, registered capital of 90 million, is a biopharmaceutical company focused on antibody therapeutics development in immune related diseases. Our strategy is to develop antibody therapeutics to meet EU and FDA quality standards. Our funder includes oversea PhD holder Dr Yu Guoliang, and Chinese biopharmaceutical industry veteran experts. The corety members have extensive biopharmaceutical industry experience including Genentech and several other international top biopharmaceutical companies. Other team members also have at least 10 years working experience on innovative antibody drug research and development as well as project management experience. The company's existing laboratory and pilot workshops cover a total area of about 2,000 square meters. Our current R&D pipeline consists of eight projects including six innovative drug and two biosimilar drug development in immune related diseases treatment, such as psoriasis, rheumatoid art

2020-10-22 22:53:32